FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200462421> ?p ?o ?g. }

• W4200462421 endingPage "876" @default.
• W4200462421 startingPage "728" @default.
• W4200462421 abstract "Most of the diseases for which apheresis therapy is indicated are intractable and rare, and each patient has a different background and treatment course prior to apheresis therapy initiation. Therefore, it is difficult to conduct large-scale randomized controlled trials to secure high-quality evidence. Under such circumstances, the American Society for Apheresis (ASFA) issued its guidelines in 2007, which were repeatedly revised until the latest edition in 2019. The ASFA guidelines are comprehensive. However, in the United States, a centrifugal separation method is mainly used for apheresis, whereas the mainstream procedure in Japan is the membrane separation method. The target diseases and their backgrounds are different from those in Japan. Due to these differences, the direct adoption of the ASFA guidelines in Japanese practice creates various problems. One of the features of apheresis in Japan is the development of treatment methods using hollow-fiber devices such as double filtration plasmapheresis (DFPP) and selective plasma exchange and adsorption-type devices such as polymyxin B-immobilized endotoxin adsorption columns. Specialists in emergency medicine, hematology, collagen diseases/rheumatology, respiratory medicine, cardiovascular medicine, gastroenterology, neurology, nephrology, and dermatology who are familiar with apheresis therapy gathered for this guideline, which covers 86 diseases. In addition, since apheresis therapy involves not only physicians but also clinical engineers, nurses, dieticians, and many other medical professionals, this guideline was prepared in the form of a worksheet so that it can be easily understood at the bedside. Moreover, to the clinical purposes, this guideline is designed to summarize apheresis therapy in Japan and to disseminate and further develop Japanese apheresis technology to the world. As diagnostic and therapeutic techniques are constantly advancing, the guidelines need to be revised every few years. In order to ensure the high quality of apheresis therapy in Japan, both the Japanese Society for Apheresis Registry and the guidelines will be inseparable." @default.
• W4200462421 created "2021-12-31" @default.
• W4200462421 creator A5000264811 @default.
• W4200462421 creator A5000535152 @default.
• W4200462421 creator A5002670120 @default.
• W4200462421 creator A5003998870 @default.
• W4200462421 creator A5004763128 @default.
• W4200462421 creator A5005922077 @default.
• W4200462421 creator A5006802039 @default.
• W4200462421 creator A5009124355 @default.
• W4200462421 creator A5009786996 @default.
• W4200462421 creator A5011234786 @default.
• W4200462421 creator A5012216609 @default.
• W4200462421 creator A5012516255 @default.
• W4200462421 creator A5012880747 @default.
• W4200462421 creator A5013446598 @default.
• W4200462421 creator A5013877873 @default.
• W4200462421 creator A5015216142 @default.
• W4200462421 creator A5015519992 @default.
• W4200462421 creator A5016313699 @default.
• W4200462421 creator A5018853775 @default.
• W4200462421 creator A5018871494 @default.
• W4200462421 creator A5018938128 @default.
• W4200462421 creator A5021287958 @default.
• W4200462421 creator A5021633231 @default.
• W4200462421 creator A5021891361 @default.
• W4200462421 creator A5024192180 @default.
• W4200462421 creator A5025162375 @default.
• W4200462421 creator A5025171057 @default.
• W4200462421 creator A5025856370 @default.
• W4200462421 creator A5026145574 @default.
• W4200462421 creator A5026303520 @default.
• W4200462421 creator A5027555116 @default.
• W4200462421 creator A5028921297 @default.
• W4200462421 creator A5030917108 @default.
• W4200462421 creator A5031205805 @default.
• W4200462421 creator A5031543446 @default.
• W4200462421 creator A5032417336 @default.
• W4200462421 creator A5032670400 @default.
• W4200462421 creator A5034518691 @default.
• W4200462421 creator A5036693411 @default.
• W4200462421 creator A5037755032 @default.
• W4200462421 creator A5039457246 @default.
• W4200462421 creator A5040408001 @default.
• W4200462421 creator A5041904549 @default.
• W4200462421 creator A5044229937 @default.
• W4200462421 creator A5044442302 @default.
• W4200462421 creator A5045179450 @default.
• W4200462421 creator A5046698599 @default.
• W4200462421 creator A5046816913 @default.
• W4200462421 creator A5047988129 @default.
• W4200462421 creator A5048621412 @default.
• W4200462421 creator A5048904998 @default.
• W4200462421 creator A5050174790 @default.
• W4200462421 creator A5052766404 @default.
• W4200462421 creator A5052820334 @default.
• W4200462421 creator A5054984833 @default.
• W4200462421 creator A5055879912 @default.
• W4200462421 creator A5058710518 @default.
• W4200462421 creator A5058916312 @default.
• W4200462421 creator A5060961911 @default.
• W4200462421 creator A5064249119 @default.
• W4200462421 creator A5065214964 @default.
• W4200462421 creator A5065443275 @default.
• W4200462421 creator A5066375815 @default.
• W4200462421 creator A5066873100 @default.
• W4200462421 creator A5067408189 @default.
• W4200462421 creator A5067597137 @default.
• W4200462421 creator A5071770530 @default.
• W4200462421 creator A5073121970 @default.
• W4200462421 creator A5073502331 @default.
• W4200462421 creator A5074616369 @default.
• W4200462421 creator A5074809722 @default.
• W4200462421 creator A5075860098 @default.
• W4200462421 creator A5075962830 @default.
• W4200462421 creator A5076021680 @default.
• W4200462421 creator A5076893733 @default.
• W4200462421 creator A5076909016 @default.
• W4200462421 creator A5078776603 @default.
• W4200462421 creator A5078870720 @default.
• W4200462421 creator A5079560395 @default.
• W4200462421 creator A5079755926 @default.
• W4200462421 creator A5081299624 @default.
• W4200462421 creator A5083189703 @default.
• W4200462421 creator A5087125829 @default.
• W4200462421 creator A5087232721 @default.
• W4200462421 creator A5088334303 @default.
• W4200462421 creator A5088480321 @default.
• W4200462421 creator A5090194514 @default.
• W4200462421 creator A5091360875 @default.
• W4200462421 creator A5091610124 @default.
• W4200462421 creator A5091826674 @default.
• W4200462421 creator A5080368941 @default.
• W4200462421 date "2021-12-01" @default.
• W4200462421 modified "2023-10-17" @default.
• W4200462421 title "The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis" @default.
• W4200462421 cites W1685331907 @default.
• W4200462421 doi "https://doi.org/10.1111/1744-9987.13749" @default.

• next